Lisinopril
Thoracic Cancer
UNC Lineberger Comprehensive Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
10 Active assets in the Thoracic Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lipitor UNC Lineberger Comprehensive Cancer Center | Phase 2 | CCC |
tng462 Tango Therapeutics, Inc. | Phase 1/2 | CC |
Eloxatin Tango Therapeutics, Inc. | Phase 1/2 | CC |
FLUOROURACILUM Tango Therapeutics, Inc. | Phase 1/2 | CC |
Rmc-6236 Tango Therapeutics, Inc. | Phase 1/2 | CC |
View all 10 →
Same molecule, other indications
Lisinopril is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →